OBJECTIVE: To assessthe impact of education on physicianadherence to therenal dosing recommendation foreptifibatide at 2academic medical centers.The primary outcomemeasurewas theproportionofpatients with renalimpairmentdosed appropriately with eptifibatide beforeand after in-service education providedbyaclinicalpharmacist. Secondary outcome measures included thedifference in theimprovement in dosing adherence between the2sitesand theinfluence of patientvariables on theincidence of bleedingevents. At site A, a1-hour educational seminaronACS management strategies wasemployed, in which5minutesfocused on adherence of prescribers to theguideline forrenal dosing recommendationsfor eptifibatide.This tutorialwas accomplished through(1) an in-service providedby1clinical pharmacisttothe cardiology department, and(2) handouts containingthe renaldosingrecommendationsfor eptifibatide alongwithdosingfor other medicationsusedtomanageACS.
TheinterventionatSite Binvolved an eptifibatide-focused seminar presented to cardiologists by aclinicalpharmacist, 10 minutesofwhich wasdevoted to renaldosingrecommendationsthatincluded (1) asummary of literature supporting theinfusionrate reduction in patie ntswith renalimpairmentand (2)the specificupdated dosing recommendation foreptifibatide.The data collected in retrospectivechart review included patientdemographics, baseline laboratoryvalues, andrisk factorsfor bleeding. An appropriate eptifibatide dose wasdefined as aphysician orderfor acontinuousinfusionof1mcg per kg per minute in patients with an estimated CrCl <50mlper minute.
RESULTS:Atotal of 148patients with renalimpairmentwho received eptifibatide were evaluated(106inthe preeducation phaseand 42 in the posteducation phase).Asignificant increase in theadherence rate for eptifibatide dosing in patients with renalimpairmentwas observed from36.8% in thepreeducation phaseto69.0% in theposteducation phase(P <0.001) for the2sitescombined. Theincidence o fmajor andminor b leedingwas 16 .7% in thepreeducation phaseand 14.3%inthe posteducation phase(P =0.742). When bleedingincidence wasstratified by theappropriateness of infusion, the incidence of majorand minorbleedingwas also similar forappropriatedosing (1 mcg per kg per minute,16.4%)versus inappropriate dosing (2 mcg per kg per minute,15.7%; P =0.916).
CONCLUSION:Thiseducational intervention providedbyaclinicalpharmacist wasassociated with improved prescriberadherence to dosing recommendations foreptifibatide in patients with renalimpairment. Improved adherence to the dosing guideline andadministration of an appropriateinfusionrate were not associated with reductionineitherminor or majorbleedingevents.
What is alreadyknown aboutthissubject

What this studyadds
•U se of platelet glycoproteinIIb/IIIainhibitorsinpatientswith non-ST-segment-elevation ACSr educes ischemic complicationsbeforeand after percutaneous coronary intervention but is associated with an increased risk of bleeding, ande ven greaterh emorrhagic risk has been reported in patients with renal impairment.
•T he acutenature in whicheptifibatideispreparedand administeredinthe cardiaccatheterization laboratory or emergency department does notpermitp harmaciste valuationo rthe use of acomputerized dosing system.
•T herea re 2c ommont ypes of interventionsi ntendedt o improve adherence to medication dosing guidelines:education programsand computerized dosing aids.
•T hisi nterventioni nvolving pharmacist-directed educationo f prescriberst or educet he dose of eptifibatide to 1m cg perk g perm inutef or patients with renal impairment wasa ssociated with improveda dherence to thed osingr ecommendation( the intermediate,process outcome)but no change in theproportion of patients whoexperienced major or minor bleeding episodes (end point, clinicaloutcome). These resultscannotbeattributed to theintervention, sincethisstudy lacked acontrol group.
BRIEFCOMMUNICATION
M edicatione rrorsc onstituteamajorp roblem in hospitalizedp atientsa nd area ssociated with increased morbiditya nd mor tality. 1,2 TheI nstitute of Medicine reported in 1999 thatmorethan98,000 people dieeachyearas aresultofmedicationerrors. 3 Furthermore, preventableadverse drug events (ADEs) area ssociated with a4 .6-day increase in a hospital stay with an estimated annual cost of $2.8 million for a7 00-bedinstitution. [1] [2] [3] [4] Anticoagulanta nd antithrombotic agents arec ited as frequents ources of thesem edicatione rrors. 1, 5 The Institute of Safe Medication Practicesh as classifieda ntithrombotic agents as high-alert medicationsbecause of theirpotentialto cause significantp atient harm. 6 In as tudy by Fanikosa nd colleagues,anticoagulantdrugs represented 7.2% of allmedication errors;a nticoagulants accounted for1 .72o fat otal of 24 medication errors per1 0,000 patient-days. 5 Similarly, in ar etrospective study, Saxera nd colleagues compared act ual doseso fl epirudin with guideline-recommendedd oses in patients with heparin-induced thrombocytopenia andr enal insufficiency. 7 The authorsf ound that6 7% of patients who experiencedam ajor bleeding eventd uringt herapyr eceived agreater thanrecommendedinitialinfusionrate.
More In addition to thefindingso fthe CRUSADEinvestigators, severalarticlesdescribed theincidence andcostimplications of ADEs.D osinge rrorsw erefrequentlyi dentifiedasamajor preventableADE.Althoughthe classes of medicationsvaried widely,anticoagulants werefrequentlycited as theculprit of preventableADE. 4, 9, 10 Despitearticlesdescribingthe frequency andp reventability of ADEa ssociated with anticoagulant anda ntiplateleta gents,n ol iterature describest he impact of pharmacy-drivene ducationt oi mprove dosing adherence by physiciansf or thesea gentsi nt he managemento fA CS. Becauseo ft hisl acko fd ata, we developedf ormale ducation programs foro ur health care professionalso na ppropriate dosing of eptifibatide,ag lycoproteinI Ib/IIIai nhibitor,i n patients with renal insufficiency.
The purposeo fthisstudy wast oc ompare thed osinga ppropriateness of eptifibatide in pat ientsw ithr enal impairment before andafter educationprogramsat2academicmedical centers.Thisstudy wasapprovedbythe institutionalreviewboards at both institutions.
Methods
Patients
We proposed thatp harmacy-driven educationa t2a cademic medicalc enters wouldi mprove adherencet or enal dosing recommendations fore ptifibatide. On theb asis of thee ptifibatide package insert,p atientsw itha ne stimated CrCl <5 0m lp er minuterequire a50% reductioninthe continuous infusionrate, from 2mcg perkgper minuteto1mcg perkgper minutewith no changest ot he bolusd ose( 180m cg perk g). 11 Eptifibatide remainsc ontraindicated in patients on hemodialysis.T hese recommendations provided theb asis foro ur inclusiona nd exclusioncriteria.
Patients weree ligiblef or inclusioni ft heyr eceivede ptifibatide fort he medicalm anagemento fu nstablea ngina( UA)o r non-ST-elevation myocardial infarction( NSTEMI), or as adjunct therapyinpercutaneouscoronaryintervention forchronic stable angina (CSA), UA,N STEMI, or ST-elevation myocardial infarction (STEMI). Eptifibatide is approvedbythe US Food andDrug Administration (FDA) fort he medicalm anagemento fU Aa nd NSTEMI,asw ellasthe interventional management of CSA, UA, andN STEMI. Administration of eptifibatide in STEMIi sn ot an FDA-approvedi ndicationa nd thereforer epresentso ff-label use. However,e ptifibatideu se as an adjunct to thei nterventional management of STEMIi sg iven aG rade IIbr ecommendation where" treatment mayb ec onsidered" by the2 005A merican HeartAssociation (AHA)/AmericanCollege of Cardiology (ACC)/
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Societyfor Cardi ovascularAngiography andInterven tionsguideline update forpercutaneouscoronaryinterventionand the2004 AHA/ACCg uideline update fort he management of STEMI. 12, 13 Additional inclusioncriteriawereage ≥ 18 yearsand an estimated CrCl <50m lp er minute, as calculated by theC ockcroft and Gaulte quation. 14 Actualb odyw eightw as usedi nt he calculation of CrCl,according to therecommendationfromMillennium Pharmaceuticals. CrCl wascalculated from values closestt o, but notf ollowing,e ptifibatidei nitiation.W ee xcludedp atientsi f fibrinolytic therapywas administered within 48 hourspreceding eptifibatide administration.All patients receivingeptifibatideduringthe pre-andposteducationphaseswereassessed forinclusion, usingthe inclusion/exclusioncriteriadescribed above.
StudyDesign
Thes tudy wasd ivided into 2p hases: thep reeducationp hase andthe posteducationphase. In thepreeducation phase, we performed ar etrospective eptifibatide utilization evaluation to identify eligible patients from June 2003 throughApril 2005 forSiteA andfromJune2003throughMay 2005 forSiteB.June2003was selected as thestartingdatebecause it correlated with therelease of ther enal dosing recommendations. We reviewed medical records to abstract patients'a ge, gender, comorbidities, concomitant antiplatelet/anticoagulantm edications,renal function before administration of eptifibatide,h ematologics tatus,b lood product transfusions, ande ptifibatided osea dministered.T hese data are summarized in Table1 .T he actual eptifibatide dose wasc omparedw itht he recommendedr enal dosing guidelinef or appropriateness,defined as aphysician orderfor acontinuousinfusion of 1m cg perk gp er minutei np atientsw itha ne stimated CrCl <50mlper minute. The preeducation andposteducationphases usedthe sameinclusion criteria,exclusion criteria,and methods of patienti dentificationa nd data abstraction. The eptifibatide utilization evaluation in thep osteducationp hasew as conducted from Mayt hroughD ecember 2005 forS iteAa nd from June throughDecember 2005 forSiteB.
Education Programs
The2s ites used slightly differente ducationali nterventions fore ptifibatided osing. Site Ai ncorporated theu pdated dosing recommendations as part of al argers eminar on ACS, whereas Site Bprovidedaneptifibatide-focusedseminar.Bothsites developed an ACSt reatment pathwayt hati ncluded all appropriate therapeutico ptions andi ncorporated dosing andm onitoring recommendations.The educationregarding thereduced dose for eptifibatide in patients with renalimpairmenttookplace at Site A in April2005and at Site BinMay 2005.
Thee ducational intervention at Site Aincluded a1 -hours eminaronACS management strategies.The in-service presentation by 1c linicalp harmacistf ocused on ther ecommendations from the CRUSADEtrial,which recommendsaggressiveand earlyantiplateleta nd anticoagulantt herapy forp atientsp resentingw ithA CS.
Review of therenal dosing of eptifibatide occurred over 5minutes during thep resentationa nd covered thei nfusionr atea djustment andthe useo fC rClini dentifying an appropriate infusionrate. A pocketreference card thatincludedrenal dosing recommendations foreptifibatidewas distributed.The in-service presentation at Site A wasattendedbyapproximately 80%ofthe cardiology department andincludedcardiologists, nurses,and houseofficers.
The intervention at Site Be mployeda1 0-minutee ptifibatidefocusede ducational program. Onel ecturew as provided to the interventional andc linicalc ardiologistsb y1clinicalp harmacist whod escribed eptifibatide renald osingr ecommendations in the medicalm anagemento fU Aa nd NSTEMI andt he interventional management of CSA, UA,N STEMI, andS TEMI.T hiss eminar detailedthe resultsfromthe ESPRIT (Enhanced Suppressionofthe Platelet IIb/IIIaReceptorWithIntegrilinTherapy)trial andGretler andc olleagues' pharmacokinetica ssessmento fe ptifibatidei n patients with renal impairment. 15, 16 These studiesprovidedthe data to update ther enal dosing recommendationf or eptifibatide.T he seminar concludedwithar eviewo fthe Cockcroft-Gaulte quation to calculatea ne stimated CrCl.P hysiciansw ereg iven ah andout of thei nformation covereda long with phone numberst oc ontact thecentral pharmacy to assistthemwithcalculatinganestimated CrCl.A pproximately 67%o ft he cardiologistsa ttendedt hisi nservicepresentationatSiteB.
Outcomes
Thep rimary outcome measure wast he overall adherence rate to eptifibatide renal dosing reco mmendationsp re-a nd posteducation. Adherencet othe dosing recommendationw as definedasaphysician orderfor acontinuous infusionof1mcg perk gp er minutei np atientsw itha ne stimated CrCl <50m l perm inute. Ours econdaryo utcome measurew as thed ifference in adherence ratesb etween Site Aa nd Site Bt oi dentify differencesi nt he effectiveness of thee ducationalp rograms. The safetyo utcome measurew as then umbero fh emorrhagic events observed pre-andp osteducationa nd as af unctiono f infusionappropriateness.
Independent, patient-specific variablesw erea lsoa ssessed fort heir associationw ithb leedinge vents. The incidenceo f hemorrhage wasd efined ands tratified basedo nt he criteria definedb yt he ThrombolysisI nM yocardialI nfarction( TIMI) studyg roup. 17 Minorb leeding wasd efined as overtb leeding associated with ad ecreasei nh emoglobinb etween 3ga nd 5g perdLora9%-15%decreaseinhematocrit. Majorbleeding was definedasanintracranialhemorrhageorovert bleeding associated with adecreaseinhemoglobin>5gper dL or >15% decrease in hematocrit.A ny bleeding wasd efined as thec omposite of minor andmajor bleeding.
To accountf or transfusions of packedr ed blood cells, the absoluten umbero fu nits transfused wasa dded to thed ifference between theb aselineh emoglobina nd thep osttransfusion hemoglobint oo btainatruereflectiono fb lood loss to be stratiAssessmentofEptifibatideDosinginRenalImpairmentBeforeand AfterIn-Service Education Provided by Pharmacists fied by thecriteriaabove.Bleedingassessments were performed by reviewinglaboratorydataand chartreviewfor annotationsof overtorintracranial bleeding.
StatisticalAnalysis
Summarys tatistics, including1 -way and2 -way contingency tables,w erec omputed fori nitiale xploratorya nalyses. In the 2-groupa nalysis, continuous variablesw erea ssessed viat he Wilcoxon rank sumt est. Dichotomous comparisons, including eptifibatide dosing adherencerates in thepre-and posteducation phases andb leedingi ncidence as af unctiono fe ducationa nd infusionappropriateness,wereassessed by either theFisherexact test or theP earson chi-squaret est, dependingo nt he expected valueineachofthe 4cells. Twologisticregressionanalyseswereconducted.Inthe first analysis, theadherence rate (dependent variable)was assessed as afunctionofthe stu dy site andeducatio nalphase(indepen dent variables) usingm ultivariate, multinomiall ogisticr egression with backwardsstepping. Studysiteand educationalphase were selected as independentvariables to determineifthe educational interventionsconducted at thestudy siteswereassociated with ad ifference in dosing adherence.W ed id noti nclude patient characteristicsascovariatesinthisequationbecause ourfocus wast od eterminet he impact of thee ducational programa s opposedtofactors contributingtoexcessdosing.
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In thesecond logistic regression analysis, thebleedingrate (dependent variable)w as assesseda saf unctiono fi nfusion appropriateness by thei ndependent variables; percentage abovei deal bodyw eight; hourso fe ptifibatidei nfused;a ge >80years;weight<6 5kg; CrCl ≤ 30 ml perminute; female gender; use of aspirin, clopidogrel, UFH,e noxaparin, warfarin, or nonsteroidal anti-inflammatoryd rugs;o rah istory of coronary artery disease, chronicr enal failure, cerebrovasculard isease,p eripheralv asculard isease,a bdominal aortic aneurysm,h eart failure,o rd iabetes, usingm ultivariable, multinomiall ogisticr egressionw ithb ackwards stepping. Thei ndependent variablesw eres elected forl ogisticr egression analysisf or bleeding to determinei fe stablishedr isk factorsa ssociated with increasingb leedingr iska sw ella s otherc ardiovascularc omorbiditiesw erea ssociated with an increasedl ikelihood of ah emorrha gice vent.C ontinuous independentv ariables,i ncludingp ercentagea bove ideal bodyw eight, hourso fe ptifibatideinfusion, age, actual body weight,a nd CrCl wered ivided into ranges andw eret reated as categorical variables.
Goodness of fitf or logistic regression analysis wasa ssessed usingt he McFadden's rho-squared statistic, analogoust oa n R 2 .A nalysesw erep erformed usingS ystatv ersion 11,S ystat Software Inc.,Richmond,California.
Patients undergoing coronary artery bypass grafting( CABG) weree xcludedf romt he bleeding analysiss ince intraoperative blood productu se woulds kewt he incidenceo fh emorrhage. Patientsw ithi ncompleted atas etsw eree xcluded from logistic regression analysis,ascalculationscould notbeperformed withoutall tested variables.
Results
Atotal of 106patientsinthe preeducation phaseand 42 patients in theposteducationp hase wereincludedinthisanalysis. No differencesb etween phases werei dentifiedw ithr espect to age, gender,o rl ength of hospitalization( Table1 ). In addition, both groups hadas imilar averagen umbero fc omorbidities( P = 0.517).However,inthe preeducation phase, significantlym ore patients presented with UA ( P <0.001). Furthermore, although statisticaldifferenceswerefound betweengroupswithrespect to baseline CrCl (preeducation phase3 3.8m lp er minutev s. posteducationp hase3 0.2m lp er minute[ P =0 .039]);t hese were notclinicallysignificant.
Impact of Education on Adherence
Asignificantly larger percentage of patients receivedanappropriatei nfusiono fe ptifibatidei nt he posteducationp hase (69.0%) thaninthe preeducation phase( 36.8%; P <0.001,T able 2).
Impact of Educational Program Type on Adherence
Site Aincluded77and 29 patients in thepreeducation phaseand theposteducationphase,respectively. Site Benrolled29patients in thep reeducation phasea nd 13 in thep osteducationp hase. Both sitesexperienced astatisticallysignificant absoluteimprovement in dosing adherencef or eptifibatide (SiteA :3 1.3%, P = 0.005, Site B: 34.7%, P =0.049;T able 2).L ogisticr egressiono f eptifibatide infusionappropriateness wasassessedasafunction of studyp hase ands ite. At otal of 148p atientsw erei ncluded in this analysis.T hisa nalysisd id noti dentifya ny significant relationship betweens tudy site (OR=0.98, P =0.986)o rt he interactionbetween site andp hase (OR=1.162, P =0.860). The McFadden's rho-squared statisticf or this analysis was0 .063. Thel acko fad ifferenceo bserved betweent he 2s ites in comparisono fthe preeducation andp osteducationp hasessuggests thatthe 2intervention methodshad similareffects in improving theadherence to renal dosing of eptifibatide.However,the small andu nequal samples izes reducedthe power to detect ad ifference in theeducational intervent ions.
Bleeding
Afterr emovingd ataf or patients whow ento nt oC ABG, we included 131p atientsi nt he initialb leedinga nalysis. Data for patients whor eceivedCABGw erer emoved in accordance with theT IMI bleeding criteria,a st he transfusion requirements for this population skew bleeding results. At otal of 11 minor and 10 majorbleedingeventsoccurred.
Table3describes bleeding incidenceasafunctionofstudy phase. Minorb leedingo ccurredi n8p atients( 8.3%)i nt he preeducation phasea nd in 3p atients( 8.6%)i nt he posteducationp hase ( P =0.965). Majorb leedingi nt he pre-and posteducationp haseso ccurredi n8p atients( 8.3%)a nd 2 patients (5.7%),respectively( P =0.617). When thesepatients were stratified by eptifibatide infusiona ppropriateness, minor bleeding occurred in 5patients(8.2%)who received an appropriate infusionand in 6patients(8.6%)who received an inappropriate infusion( P =0.939). Majorb leedingo ccurred in 5patients(8.2%)who received an appropriate infusionand in 5p atients( 7.1%)w ho received an inappropriate infusion ( P =0 .821). Table4s ummarizest he bleeding incidencea sa function of infusiona ppropriateness.
Aftert he initialb leedinga nalysis, we performedl ogistic regressiont oi dentifyo ther potentialr iskf actors forb leeding. Data summarizingt he bleeding responsesa nd patientc haracAssessmentofEptifibatideDosinginRenalImpairmentBeforeand AfterIn-Service Education Provided by Pharmacists teristicsare summarized in Table5.Because of thelarge number anddistributiono fv ariables assessed andthe uneven distribution of minor and majorb leeding, p atientsw eres tratified as having anyb leeding( minor or major) or no bleeding.A sw ith theinitialb leedinganalysis, patients whor eceivedCABGw ere excluded from analysis. Patientsw ho didn ot have complete data sets were also excluded,a sl ogisticr egressionc ould not be performedo ni ncomplete data sets.M ost commonly,t hese patients didn ot have ah eighta nnotated foru st oc alculate an ideal bodyweight.
Afterthese patients were removed, 119w erel eftf or analysis. At otal of 17 (8 minor,9major)b leedingeventsw erei dentified, usingthe bleeding criteria establishedbythe TIMI studygroup. Of thee stablisheda nd hypothesized risk factorsf or bleeding( female gender,a ge >8 0y ears;i nfusiona ppropriateness; CrCl <30mlper minute; ahistory of chronicrenal failure, heart failure, or diabetes), only age>80 yearsw as associated with significantlyi ncreased odds of bleeding (OR=4 .74, 95%C I, 1.45-15.38,P=0.010). The McFadden's rho-squared statisticf or this analysis was0.101.
Discussion
Ourchallenge wast od evelop an educationalp rogram to educate physiciansnot only on theupdated dosing of eptifibatide, buta lsoo nt he assessment of renalf unc tion in patients to determinet he optimald ose. Aw ealth of literature exists on educationalp rogramst oi ncreasep hysician awarenessa nd recognition of disease states as well as strategies to improve prescribingo fm edications.H owever,n or eports detail educational strategies to optimize thed ose of medicationst om anagedisease. Despitethislimitation, we developedand applied educationalstrategies similartothose foundinthe literature to increasedisease stateawarenessand adherence to disease state management guidelines. [18] [19] [20] Schunemann andcolleaguesconducted an assessment of physician opinion regardingeducational strategies to improveguideline adherence as part of theSeventh American CollegeofChest PhysiciansC onferenceo nA ntithrombotica nd Thrombolytic Therapy. 18 Theirr esults identified disseminationo fp rinted information ande ducationals eminarsa sp referred methods thatp hysiciansb elievedw ould result in increaseda dherence. Theyalsoacknowledged active strategies,suchascomputerized reminders andp atient-focusedi nterventions,a se stablished methodsbywhich adherence maybeimproved.
Thesef indingsw eree choedb yT ooher andc olleaguesi n theirreviewofstrategies to improvevenousthromboembolism (VTE)p rophylaxis. 20 Their review assessed thee ffectiveness of educationals trategiest oi mprove prescribingo fa gentsf or VTEprophylaxis. The authorsidentifiedcontinuingeducation, auditand feedback,computer-baseddecisionaids, documentation aids,a nd qualitya ssurance strategies as amongt he best ways to improveprescribing of VTEprophylaxis. They further went on to suggestthatm ultipleeducational strategies involvingactive programs likecomputerizedreminders maybemore effective thanasinglestrategy.
Thei ncidence of minor andm ajor bleeding events did nots ignificantly change betweent he preeducation (16.7%) andp osteducation phases (14.3%). Theo verall bleeding rates appearedt ob ee levated in comparison with ratesr eported by large, prospective trials evaluatingt he safety ande fficacy of eptifibatide in patients irrespective of renal function.I n theI ntegrilint oM inimise Platelet Aggregationa nd Coronary Thrombosis-II( IMPACT-II) trial, 2,682p atientsw erer an- domizedt or eceive a1 35 mcg perk gb olus o fe ptifibatide followed by continuousi nfusiono f0 .5 mcg or 0.75 mcg per kg perm inute. 21 The incidenceo fm ajor bleeding was5 .1% and5 .2%i ne achg roup,r espectively. Ther ateo fm ajor and minor bleeding in 4,679p atientsw ho receivede ptifibatide as a1 80 mcg perk gp er minuteb olus followe db ye ithera 1.3m cg or 2m cg perk gp er minutei nfusioni nt he Platelet GlycopoteinIIb/IIIainUnstableAngina: Receptor Suppression UsingI ntegrilinT herapy( PURSUIT) clinical trialw as 14.0% fort he subset of patients whod id notu ndergoC ABG. 22 In the1 ,040 patients randomized to receive two1 80 mcg per kg boluseso fe ptifibatidef ollowedb yc ontinuousi nfusiono f 2mcg perkgper minuteinthe ESPRIT trial, 4.8% of patients experiencedamild, moderate,orseverebleedingevent. 15 In all3studies,the authorsencouragedthe useofaspirin and heparint herapy as part of standard ACSc are. In theP URSUIT study, 93%o fp atientsw erea dministered aspirina nd 89.8%o f patients receivedheparin. 22 These values aresimilar to aspirinand heparinuse researchersfound in ourstudy (see Table1 ) . Data on theuse of aspirinand heparinfor theIMPACT-II andESPRITtrialswerenot reported.The most notablevariablethatmay explain thedifferenceinbleedingrates betweenour resultsand thesetrialsi st he presence of renali mpairment. We specificallye nrolled patients with aCrCl<50 ml perminute, whereasthe IMPACT-II, PURSUIT, andESPRITtrialsenrolledpatientsirrespective of renal function.F urthermore,o ur patientp opulationa ppearedt oh ave an oldermeanage (75.6years in thepreeducation phaseand 77.8 yearsinthe posteducationphase)comparedwiththe population in theIMPACT-II (62years in thegroup receiving0.5 mcg perkgper minuteand 60 in thegroup receiving0.75mcg perkgper minute), PURSUIT( 64 years),and ESPRIT (62years)trials. 15, 21, 22 Also,our studya ppearedt oh avem oref emalep atients( 46.2%i nt he preeducationphaseand 45.2%inthe posteducationphase) compared with theIMPACT-II (25.6%), PURSUIT(34.9%), andESPRIT(27%) trials. 14, 20, 21 Last,t he median weight of ourp atient population (74kginthe preeducation phaseand 70 kg in theposteducation phase) appearedt ob el ower thant hati nt he IMPACT-II (83k gi np atientsw ho received0 .5 mcg perk gp er minute and84kginpatientswho received 0.75 mcg perkgper minute), PURSUIT( 78 kg), andE SPRITt rials( 84 kg). 15, 21, 22 Whilet he significance of thed ifferences in thesev ariables between our data andt hose of other researchersi su nknown,o ur population appears to be at higher risk forreceiving greaterthanrecommended doseso fe ptifibatideand increased risk of bleeding associated with olderpatient age, alargerpercentageoffemalepatients,and lower actual bodyweight.
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Limitations
Firsta nd foremost amongt he limitations of this studyw as the absenceofacontrol group. Therefore, we cannotbecertain that oure ducationali ntervention was ther easonf or thei mproved adherencetothe dosing guidelineinpatientswithrenal impairment.Second,wechose to define theprimary outcome measure as an intermediate measure (infusiona ppropriateness)a nd the proportion of patients whoexperienced either amajor or minor bleeding episode as thes econdary outcome.O ur assumption wast hata dherence to renal dosing recommendations would result in adecreaseinhemorrhagic complications. Third, thes mall andu nequal samples izes in thep reeducation andp osteducationp hases contributed to thea bsence of as ignificant differencei nt he i ncidence of minor andm ajor hemorrhagice ventsi nt hisa nalysis. Logistic regression demonstrated an increasedl ikelihood of bleeding in patients >80 years. We anticipated an increasedr isko fb leedingi np atients in whom eptifibatides erum concentration should be elevated (history of chronicrenal failure,CrCl<30 ml perminute, inappropriatei nfusionr ate, prolongedi nfusion).H owever,n oneo f thesef actors wasa ssociated with increasing patients'b leeding risk,mostlikelydue to thesmall sample size in ourstudy.
Thepharmacokinetic studyreported by Gretler andcolleagues demonstrated a2 -foldi ncreasei ns erum steady-state concentrationso fe ptifibatidea nd a5 0% decreasei nt otal clearanceo f eptifibatide in patients with aC rCl<50 ml perm inute. 16 These pharmacokineticdataservedasthe foundation forthe renal dosing recommendations fore ptifibatidea so pposed to actual observed bleeding ratesb etween thec ohortso fp atientswithr enal impairment.While ourstudy resultsare only descriptive, the16% average rate of minor andm ajor bleeding combined forb otha ppropriate infusion( 1mcg perkgper minute) andinappropriate infusion( 2 mcg perkgper minute) suggests thatfurther research is warranted in eptifibatide use in patients with renal impairment.
Conclusion
To ourk nowledge, this is thef irst studyi nw hich researches investigated thei mpacto fp harmacist-drivene ducation to improved osingo fa na ntiplatelet agenti nt he management of ACS. Thee ducation programs werea ssociated with improvement in thedosingofeptifibatideinpatientswithrenal impairment to ther ecommended dose of 1 mcg perk gper minu te in 69.0%ofpatientscomparedwith36.8% before theintervention. Thep roportiono fp atientsw ho experiencede ither majoro r minor bleeding wassimilar in the2periods, 16 .7% (16patients) in thep reeducation period and1 4.3% (5 patients)i nt he posteducationperiod, andthere wasnodifferenceinthe incidenceof majoro rm inor bleeding (approximately 16%f or both infusion ratesof1mcg or 2mcg perkgper minute).
